Cambria Pharmaceuticals eliminated some programs to focus on its most promising potential drugs and cut six of its 14 jobs.
(Erik Jacobs for The Boston Globe)
Biotech firms cutting back as capital grows scarce
Cambria Pharmaceuticals eliminated some programs to focus on its most promising potential drugs and cut six of its 14 jobs.
(Erik Jacobs for The Boston Globe)
The pain on Wall Street has spread to the hub of the Boston-area biotech industry, Kendall Square in Cambridge. Small and mid-size biotechnology firms are slashing jobs, cutting salaries, and shrinking their offices as it becomes increasingly difficult to raise capital. (Full article: 818 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
